Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0BQBWF
ADC Name	HuAD208.4.1-vcMMAE-DAR4
Synonyms	HuAD208.4.1-vcMMAE-DAR4; huAD208.4.1 vcMMAE-DAR4 Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Non-small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	huAD208.4.1		Antibody Info
Antigen Name	Leucine-rich repeat-containing protein 15 (LRRC15)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	86.91	%	EBC-1 cells	Lung squamous cell carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86.91% (Day 21)	High LRRC15 expression (LRRC15+++; IHC 3+)
Method Description	LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huAD208.4.1-vcMMAE-DAR4 (3 mg/kg) was demonstrated in EBC-1 xenografts.
In Vivo Model	EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891

References

Ref 1	Anti-huLRRC15 antibody drug conjugates and methods for their use. 2017-06-08

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.